Edgewise Therapeutics Future Growth

Future criteria checks 0/6

Edgewise Therapeutics is forecast to grow earnings and revenue by 10.1% and 70.7% per annum respectively. EPS is expected to grow by 17.4% per annum. Return on equity is forecast to be -34.9% in 3 years.

Key information

10.1%

Earnings growth rate

17.4%

EPS growth rate

Pharmaceuticals earnings growth	22.8%
Revenue growth rate	70.7%
Future return on equity	-34.9%
Analyst coverage	Good
Last updated	22 Apr 2024

Recent future growth updates

Recent updates

Edgewise Therapeutics: Behind The Massive Rally

Feb 18

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Dec 07

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Aug 16

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Apr 28

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Jan 13

Edgewise Therapeutics proposes $100M stock offering plan

Sep 13

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Aug 04

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Aug 02

Earnings and Revenue Growth Forecasts

NasdaqGS:EWTX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	12	-190	N/A	N/A	4
12/31/2025	N/A	-166	N/A	N/A	4
12/31/2024	N/A	-131	-95	-95	6
12/31/2023	N/A	-100	-98	-92	N/A
9/30/2023	N/A	-89	-86	-77	N/A
6/30/2023	N/A	-81	-77	-67	N/A
3/31/2023	N/A	-76	-72	-63	N/A
12/31/2022	N/A	-68	-58	-53	N/A
9/30/2022	N/A	-61	-53	-50	N/A
6/30/2022	N/A	-56	-48	-46	N/A
3/31/2022	N/A	-51	-41	-40	N/A
12/31/2021	N/A	-43	-34	-34	N/A
9/30/2021	N/A	-36	-29	-29	N/A
6/30/2021	N/A	-27	-24	-24	N/A
3/31/2021	N/A	-21	-18	-18	N/A
12/31/2020	N/A	-17	-15	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EWTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EWTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EWTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EWTX is forecast to have no revenue next year.

High Growth Revenue: EWTX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EWTX is forecast to be unprofitable in 3 years.

Edgewise Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 16% to US$30.50

Price target increased by 17% to US$27.40

Price target increased by 15% to US$27.40

Price target increased by 19% to US$28.75

Price target increased to US$30.00

Price target decreased to US$25.60

Recent updates

Edgewise Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Price target increased by 16% to US$30.50

Edgewise Therapeutics: Behind The Massive Rally

Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

General Counsel notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Edgewise Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $240.000002 million.

General Counsel notifies of intention to sell stock

Co-Founder recently sold US$1.6m worth of stock

Co-Founder notifies of intention to sell stock

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

New major risk - Revenue and earnings growth

Edgewise Therapeutics Announces Expansion of Their Edg-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)

Edgewise Therapeutics, Inc. Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics, Inc. Begins Dosing First-In-Human Phase 1 Trial of EDG-7500

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Price target increased by 17% to US$27.40

Edgewise Therapeutics, Inc. Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

New minor risk - Share price stability

Price target increased by 15% to US$27.40

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Price target increased by 19% to US$28.75

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics, Inc. Appoints Marc Semigran as Chief Development Officer

Edgewise Therapeutics Announces Initiation of Lynx Phase 2 Clinical Trial of Edg-5506 for the Treatment of Duchenne Muscular Dystrophy

Edgewise Therapeutics, Inc. Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy

Edgewise Therapeutics proposes $100M stock offering plan

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

General Counsel notifies of intention to sell stock

Edgewise Therapeutics, Inc. Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy

General Counsel exercised options and sold US$74k worth of stock

Price target increased to US$30.00

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics Now Enrolling Canyon Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

General Counsel exercised options and sold US$65k worth of stock

Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2000 Growth Index

Edgewise Therapeutics Inc. Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular

General Counsel exercised options and sold US$226k worth of stock

Price target decreased to US$25.60

General Counsel notifies of intention to sell stock

Price target increased to US$31.00

Edgewise Therapeutics, Inc. Anticipates Initiation of Phase 2 Trials in Individuals with BMD (NCT05291091) in the Second Quarter of 2022 and BMD in the Second Half of 2022

High number of new directors

Edgewise Therapeutics, Inc. Announces the Initiation of an Edgewise-Funded Observational Trial in Individuals with BMD

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)

High number of new directors

Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Co-Founder recently sold US$781k worth of stock

Co-Founder recently sold US$672k worth of stock

Co-Founder notifies of intention to sell stock

Edgewise Therapeutics, Inc. Announces Publication of Data Demonstrating the Elevation of Fast But Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy

Edgewise Therapeutics names new chief medical officer

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies